BM50, from a patient who had relapsed on anti-CD19 CAR-T cell therapy, contained a high percentage of cells with cell surface Galectin-1, whereas ICN06, an ETV6-RUNX positive ALL had the lowest percentage. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.